Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof

Patent metadata

Field	Value
Publication number	US-12448454-B2
Application number	US-202218566391-A
Country	US
Kind code	B2
Filing date	Jun 8, 2022
Priority date	Jun 8, 2021
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The invention pertains to the field of immunotherapy. The present invention provides specific humanized anti-CLEC-1A antibodies, antigen-binding fragments thereof and mimetics thereof, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The compounds of the invention can be used to treat deleterious conditions.

First claim

The invention claimed is:

1. An antibody or antigen-binding fragment thereof that specifically binds to the extracellular domain of human C-type lectin-like receptor-1 member A receptor (CLEC-1A receptor) and which comprises:
an antibody heavy chain variable domain comprising VHCDR1 of SEQ ID NO: 10, VHCDR2 of SEQ ID NO: 11, VHCDR3 of SEQ ID NO: 12; and
an antibody light chain variable domain comprising VLCDR1 of SEQ ID NO: 13, VLCDR2 of SEQ ID NO: 14, VLCDR3 of SEQ ID NO: 15; or
an antibody heavy chain variable domain comprising VHCDR1 of SEQ ID NO: 16, VHCDR2 of SEQ ID NO: 17, VHCDR3 of SEQ ID NO: 18; and
an antibody light chain variable domain comprising VLCDR1 of SEQ ID NO: 19, VLCDR2 of SEQ ID NO:20, VLCDR3 of SEQ ID NO:21; or
an antibody heavy chain variable domain comprising VHCDR1 of SEQ ID NO: 22, VHCDR2 of SEQ ID NO:23, VHCDR3 of SEQ ID NO:24; and
an antibody light chain variable domain comprising VLCDR1 of SEQ ID NO: 25, VLCDR2 of SEQ ID NO:26, VLCDR3 of SEQ ID NO:27.

2. The antibody or antigen-binding fragment thereof according to claim 1 , which comprises:
an antibody heavy chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:3; and an antibody light chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID No. 4, or
an antibody heavy chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:5; and an antibody light chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID No. 7; or
an antibody heavy chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:8; and an antibody light chain variable domain comprising or consisting of the amino acid sequence set forth in SEQ ID No. 9.

3. The antibody or antigen-binding fragment thereof according to claim 1 , which antagonizes the binding of the extracellular domain of human CLEC-1A to secondary necrotic cells and/or tumor cells and/or to the intracellular content of secondary necrotic cells and/or to the intracellular content of tumor cells.

4. The antibody or antigen-binding fragment thereof according to claim 1 , which antagonizes the binding of a fusion protein comprising the extracellular domain of human CLEC-1A receptor fused with a Fc fragment of a human immunoglobulin to secondary necrotic cells and/or tumor cells and/or to the intracellular content of secondary necrotic cells and/or to the intracellular content of tumor cells.

5. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody is a recombinant antibody that comprises a human IgG1, IgG2, IgG3 or IgG4 constant region.

6. The antibody or antigen-binding fragment thereof according to claim 1 , comprising an antibody heavy chain constant region that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 28, SEQ ID NO:29 and SEQ ID NO:30, SEQ ID NO:97, SEQ ID NO: 100 or SEQ ID NO: 101.

7. The antibody or antigen-binding fragment thereof according to claim 1 , comprising an antibody light chain constant region that is a kappa light chain constant region.

8. The antibody or antigen-binding fragment thereof according to claim 1 , comprising an antibody light chain constant region that comprises or consists of the amino acid sequence set forth in SEQ ID NO: 33.

9. The antibody or antigen-binding fragment thereof according to claim 1 , which binds to human CLEC-1A with an affinity constant (KD) of at least 1E-07 M.

10. The antibody or antigen-binding fragment thereof according to claim 1 , which increases when used in vivo and/or in vitro the phagocytosis of tumor cells and/or secondary necrotic cells by dendritic cells and/or macrophages, as compared to a negative control, wherein the phagocytosis of tumor cells is increased by at least 10% as compared to the negative control.

11. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to claim 1 with a pharmaceutical suitable vehicle.

12. A combination of compounds comprising a first therapeutic agent and at least one second therapeutic agent, wherein:
i) the first therapeutic agent is an antibody or antigen-binding fragment thereof according to claim 1 ;
and

ii) the at least one second therapeutic agent is selected from the group consisting of an immunotherapeutic agent, including a tumor-targeting antibody or antigen-binding fragment thereof, a chemotherapeutic agent, a cell therapy agent, a CAR-T cell, a radiotherapy agent, and a cytotoxic agent; for simultaneous, separate or sequential use of the first and the second therapeutic agents.

13. The combination of compounds according to claim 12 , wherein the tumor-targeting antibody is a monoclonal antibody or antigen-binding fragment thereof.

14. The combination of compounds according to claim 12 , wherein the tumor-targeting antibody is a tumor-targeting monoclonal antibody or antigen-binding fragment thereof which activates and/or enhances the phagocytosis capability of macrophages.

15. The combination of compounds according to claim 12 , wherein the tumor-targeting antibody is a monoclonal antibody or antigen-binding fragment thereof is a monoclonal antibody selected from the group consisting of alemtuzumab, atezolizumab, bevacizumab, cetuximab, herceptin, panitumumab, rituximab, trastuzumab, an anti-PDL-1 antibody and an anti-CD47 antibody.

16. The combination of compounds according to claim 12 , wherein the tumor-targeting antibody is selected from the group consisting of an anti-PD1 antibody, an anti-CTLA4 antibody, an agonist anti-CD137 antibody, an anti-CD28 antibody, an anti-CD127 antibody, an anti-bcl2 antibody and an anti-SIRPa antibody.

17. The combination of compounds according to claim 12 , wherein the cytotoxic agent has an anti-proliferative, pro-apoptotic, cell cycle arresting and/or differentiation inducing effect.

18. The combination of compounds according to claim 12 , wherein the cytotoxic agent is selected from the group consisting of cytotoxic antibody, alkylating drugs, anthracyclines, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, alkaloids, bleomycin, antineoplastic drugs, and cyclophosphamide.

Assignees

• Ose Immunotherapeutics
• Univ Nantes
• Inst Nat Sante Rech Med
• Inst Nat Sante Rech Med
• Univ Nantes

Inventors

• Pengam Sabrina
• Gauttier Vanessa
• Mary Caroline
• Poirier Nicolas
• Drouin Marion
• Chiffoleau Elise

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• A61K2039/505

  comprising antibodies · CPC title